表紙
市場調査レポート

Merck KGaAの製品パイプライン分析

Merck KGaA - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224551
出版日 ページ情報 英文 123 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
Merck KGaAの製品パイプライン分析 Merck KGaA - Product Pipeline Review - 2016
出版日: 2016年03月22日 ページ情報: 英文 123 Pages
概要

当レポートでは、Merck KGaAにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Merck KGaAの基本情報

  • Merck KGaAの概要
  • 主要情報
  • 企業情報

Merck KGaA:R&Dの概要

  • 主な治療範囲

Merck KGaA:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Merck KGaA:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 出願が却下された/取り下げられた製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Merck KGaA:薬剤プロファイル

  • cetuximab
  • avelumab
  • choriogonadotropin alfa
  • atacicept
  • ATXMS-1467
  • pimasertib hydrochloride
  • pimasertib hydrochloride + voxtalisib
  • sprifermin
  • tecemotide
  • tepotinib
  • BeiGene-290
  • BGB-283
  • DI-B4
  • MSB-0010360N
  • MSB-0010841
  • MSC-2015103B
  • MSC-2363318A
  • MSC-2364447
  • MSC-2490484A
  • ALX-0751
  • AS-605240
  • cilengitide
  • DDD-498
  • rimeporide
  • Small Molecule to Inhibit Aurora B Kinase for Cancer
  • Vaccine for Cancer-1
  • Vaccine for Cancer-2
  • Next-Generation Antibody-Drug Conjugates for Cancer
  • Small Molecule to Inhibit SYK for Inflammation
  • Small Molecule to Inhibit WNT Pathway for Oncology
  • Small Molecules for Multiple Sclerosis
  • Small Molecules for Oncology
  • Small Molecules to Agonize TNFR for Cancer

Merck KGaA:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Merck KGaA:最近のパイプライン動向

Merck KGaA:休止中のプロジェクト

Merck KGaA:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • abituzumab
    • anastrozole
    • atacicept
    • cilengitide
    • cladribine
    • Drug to Antagonize Oxytocin Receptor for Pre-term Labor
    • EMD-1204831
    • emfilermin
    • EML-4156
    • matuzumab
    • MSB-0010445
    • MSB-0010841
    • onercept
    • Osteopontin
    • pimasertib hydrochloride
    • plovamer acetate
    • sarizotan hydrochloride
    • tecemotide
    • tucotuzumab celmoleukin

Merck KGaA:企業発表

Merck KGaA:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07990CDB

Summary

Global Markets Direct's, 'Merck KGaA - Product Pipeline Review - 2016', provides an overview of the Merck KGaA's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Merck KGaA, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Merck KGaA
  • The report provides overview of Merck KGaA including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Merck KGaA's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Merck KGaA's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Merck KGaA's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Merck KGaA
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Merck KGaA's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Merck KGaA Snapshot
    • Merck KGaA Overview
    • Key Information
    • Key Facts
  • Merck KGaA - Research and Development Overview
    • Key Therapeutic Areas
  • Merck KGaA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Merck KGaA - Pipeline Products Glance
    • Merck KGaA - Late Stage Pipeline Products
      • Filing rejected/Withdrawn Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Merck KGaA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Merck KGaA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Merck KGaA - Drug Profiles
    • cetuximab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • avelumab
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • choriogonadotropin alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cladribine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • atacicept
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-2736
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pimasertib hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sprifermin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tecemotide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tepotinib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-283
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BGB-290
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DI-B4
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • L-Praziquantel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-1095
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-2698
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-2951
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-3814
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-7824
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-9241
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MSC-2015103B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pimasertib hydrochloride + voxtalisib
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rimeporide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALX-0751
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AS-605240
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cilengitide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • DDD-498
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-7583
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Aurora B Kinase for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit CDK8 for Colorectal Carcinoma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine 1 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine 2 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit SYK for Inflammation
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit WNT Pathway for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Autoimmune Disorder and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize TNFR for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Merck KGaA - Pipeline Analysis
    • Merck KGaA - Pipeline Products by Target
    • Merck KGaA - Pipeline Products by Route of Administration
    • Merck KGaA - Pipeline Products by Molecule Type
    • Merck KGaA - Pipeline Products by Mechanism of Action
  • Merck KGaA - Recent Pipeline Updates
  • Merck KGaA - Dormant Projects
  • Merck KGaA - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • abituzumab
      • anastrozole
      • atacicept
      • cilengitide
      • cladribine
      • Drug to Antagonize Oxytocin Receptor for Pre-term Labor
      • EMD-1204831
      • emfilermin
      • EML-4156
      • M-1095
      • matuzumab
      • MSB-0010445
      • onercept
      • Osteopontin
      • pimasertib hydrochloride
      • plovamer acetate
      • sarizotan hydrochloride
      • tecemotide
      • tucotuzumab celmoleukin
  • Merck KGaA - Company Statement
  • Merck KGaA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Merck KGaA, Key Information
  • Merck KGaA, Key Facts
  • Merck KGaA - Pipeline by Indication, 2016
  • Merck KGaA - Pipeline by Stage of Development, 2016
  • Merck KGaA - Monotherapy Products in Pipeline, 2016
  • Merck KGaA - Combination Treatment Modalities in Pipeline, 2016
  • Merck KGaA - Partnered Products in Pipeline, 2016
  • Merck KGaA - Partnered Products/ Combination Treatment Modalities, 2016
  • Merck KGaA - Out-Licensed Products in Pipeline, 2016
  • Merck KGaA - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • Merck KGaA - Filing rejected/Withdrawn, 2016
  • Merck KGaA - Phase III, 2016
  • Merck KGaA - Phase II, 2016
  • Merck KGaA - Phase I, 2016
  • Merck KGaA - Preclinical, 2016
  • Merck KGaA - Discovery, 2016
  • Merck KGaA - Pipeline by Target, 2016
  • Merck KGaA - Pipeline by Route of Administration, 2016
  • Merck KGaA - Pipeline by Molecule Type, 2016
  • Merck KGaA - Pipeline Products by Mechanism of Action, 2016
  • Merck KGaA - Recent Pipeline Updates, 2016
  • Merck KGaA - Dormant Developmental Projects,2016
  • Merck KGaA - Discontinued Pipeline Products, 2016
  • Merck KGaA, Subsidiaries

List of Figures

  • Merck KGaA - Pipeline by Top 10 Indication, 2016
  • Merck KGaA - Pipeline by Stage of Development, 2016
  • Merck KGaA - Monotherapy Products in Pipeline, 2016
  • Merck KGaA - Partnered Products in Pipeline, 2016
  • Merck KGaA - Out-Licensed Products in Pipeline, 2016
  • Merck KGaA - Pipeline by Top 10 Target, 2016
  • Merck KGaA - Pipeline by Route of Administration, 2016
  • Merck KGaA - Pipeline by Molecule Type, 2016
  • Merck KGaA - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top